News

invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it will commence operations on 1 January 2022. invIOs, a fully owned subsidiary of APEIRON Biologics AG has been assigned APEIRON’s innovative cancer immunotherapy activities and all related clinical and preclinical R&D projects. invIOs’ CEO Peter Llewellyn-Davies...

Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itself Primary objective is to evaluate safety and tolerability of inhaled APN01 Phase 1 trial to enroll about 40 healthy volunteers Additional US Phase 2 trial with intravenous administration of APN01 Press release (EN) | Presseaussendung (DE)

Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables outpatient treatment within one day from cell collection to reinfusion Phase Ib clinical trial evaluates immunological effects as well as safety and tolerability of APN401…

Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from the Supervisory Board to the newly created Scientific Advisory Board, which he will build up and lead as Chairman Additional pre-clinical data show highly promising…

APEIRON ́s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue Additional pre-clinical data show highly promising results with APN01 in various mutation variants Financing round planned to secure funding of further upcoming development...

Treatment was safe and well tolerated and no drug-related severe adverse events were observed Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed Biomarker development supports APN01’s mode of action against SARS-CoV-2 Investigators and experts recommend further development of APN01 in COVID-19 Press release (EN) | Presseaussendung (DE)

Results of the double-blind, placebo-controlled trial expected in Q1 2021 Preparations for rolling Marketing Authorization Application in Europe commenced Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation Press release (EN) | Presseaussendung (DE)

Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)